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The need for early detection of AD becomes critical as disease-modifying agents near the marketplace. Here, we present results
from a study focused on improvement in detection of metabolic deﬁcits related to neurodegenerative changes consistent with
possible early AD with statistical evaluation of FDG-PET brain images. We followed 31 subjects at high risk or diagnosed with
MCI/ADfor3years.15metcriteriafordiagnosisofMCI,andﬁvemetcriteriaforAD.FDG-PETscanswerecompletedatinitiation
and termination of the study. PET scans were read clinically and also evaluated objectively using Statistical Parametric Mapping
(SPM). Using standard clinical evaluation of the FDG-PET scans, 11 subjects were detected, while 18 were detected using SPM
evaluation. These preliminary results indicate that objective analyses may improve detection; however, early detection in at-risk
normal subjects remains tentative. Several FDA-approved software packages are available that use objective analyses, thus the
capacity exists for wider use of this method for MCI/AD.
1.Introduction
The need for earlier and more accurate detection of
Alzheimer’s disease (AD) becomes critical with the much
anticipated introduction of disease-modifying agents. The
earliestdetectablechangesinADmaywellbeinthebraintis-
sue itself, and functional brain imaging provides a noninva-
sive window directly into the brain’s activity. The utilization
of [18F]-ﬂuorodeoxyglucose (FDG) uptake by brain tissue as
measured by positron emission tomography (PET) is a well-
documented method for evaluation of brain function as well
as dysfunction. Since the earliest examinations of FDG PET
studies of brain metabolism [1], there have been reports of a
characteristic pattern of decreased brain metabolic activity
that is seen in patients with AD. This pattern is generally
distinct from that seen in other types of dementia [2, 3].
Other studies have demonstrated a relationship between the
magnitude of cognitive impairment in AD and the extent
of these metabolic deﬁcits [4, 5], important in that they
demonstrate that progression of neurodegenerative changes
isassociatedwithbothmorecognitiveimpairmentandlarger
PET metabolic deﬁcits. Other reports indicate the potential
to detect brain metabolic changes (in the same distinct
pattern seen in patients diagnosed with probable AD) across
groups of premorbid patients, who have not yet developed
MCI, before symptoms or objective neuropsychological
deﬁcits occur [6–8]. However, detecting the subtle metabolic
abnormalities associated with the early neurodegenerative
changes that eventually will lead to AD in individual patients
(rather than groups) using objective evaluation of PET
remains less commonly reported. Objective analysis of PET
brain image data has been available since the origins of
PET, but has been chieﬂy utilized in the research arena.
While there are numerous studies that report on PET brain
imaging and AD, the numbers of studies that make use
of advanced computerized digital image processing tools2 International Journal of Alzheimer’s Disease
are fewer, and fewer still are the studies which use this
technology to examine brain activity at the single-subject
level [9]( f o rr e v i e ws e e[ 10] ) .W h i l ei ti si m p o r t a n tt o
our understanding of the disease process to examine brain
activity in group studies, the use of objective statistical
image analysis enables the comparison of one brain image
to a group of control brain images at the single-voxel level.
This means of assessment is important to the clinician
as it can provide information that may have an impact
on early clinical diagnosis and management, particularly if
neuroprotective pharmaceutical strategies are achieved.
OurstudyexaminestheusefulnessofobjectivePETbrain
image analyses compared to standard (subjective visual)
interpretation of FDG-PET brain image data. This study
included a range of subjects, from individuals who were at
risk but cognitively normal through the early mild cognitive
impairment (MCI) stage. Even in the subjects who met
criteria for MCI, the average MMSE score was 28 (ﬁve
patients with probable AD were included as a reference). We
demonstrate that in this early population, 11 patients had
changes apparent on the SPM examination consistent with
early stages of possible AD, but had PET scans that appeared
normal to subjective visual interpretation—the standard of
care for reading FDG-PET brain scans today. This standard
isreviewedfurtherinthediscussion,alongwiththepotential
implications of adding objective evaluation to this standard.
T h ec a s ei sm a d ef o ro b j e c t i v eF D G - P E Ts c a ne v a l u a t i o nt o
improvethecurrentstandardforearlydetectionofmetabolic
changes consistent with possible AD.
2.MaterialsandMethods
2.1. Subjects. This research was conducted in accordance
with the guidelines and the approval of the Institutional
Review Board. Subjects were recruited from the community
with an emphasis on recruitment of subjects with MCI or
those in the at-risk cognitively normal state. All subjects
were informed of all study procedures and signed informed
consent before involvement in the study. In all, a total of
41 subjects were screened. Of these, 9 failed to meet the
inclusion or exclusion criteria, and 32 subjects were enrolled.
One subject withdrew due to sudden illness before any data
collection. (31 used, 15 male, 16 female), with an age range
from 56 to 84, with a mean age of 71 ± 8. This study focused
on early detection, speciﬁcally with regards to patients with
subjective memory loss but still not meeting criteria for
MCI. To be enrolled in the study, patients must either meet
at least MCI criteria and have no other neuropsychiatric
problems, or must both have a ﬁrst-degree relative with AD
and be APoE4+. Subjective memory loss corroborated by
friend or family member was preferred. A diagnosis of Major
Depression was not grounds for exclusion, based on the high
rate of comorbidity [11]. We also included 5 patients with
mild AD. Demographics are shown in Table 1.
2.2. Neuropsychological Testing. Patients were evaluated with
periodic neuropsychological testing (NP) a total of ﬁve times
during the study. All subjects were followed longitudinally
for three years throughout the study. The initial diagnosis
was determined by neuropsychological scores along with the
clinical evaluation.
The criteria for a diagnosis of Mild Cognitive Impair-
ment (MCI) were:
(i) memory complaint with informant corroboration,
(ii) objective memory impairment with NP testing,
(iii) normal general cognitive function,
(iv) intact activities of daily living,
(v) not demented.
These criteria were based upon the American Academy
of Neurology’s practice parameters for early detection of
dementia [12]. Neuropsychological tests used to establish
objective cognitive impairment included the Folstein Mini-
Mental State Examination, Clock Drawing Test, Trails A
& B, Boston Naming Task, Rey-Osterrieth Complex Figure
Task, and the Hopkins Verbal Learning Task. To establish
cognitive impairment, subjects must have deﬁcits on at least
two scores. If there was only one measure that was abnormal,
it was still counted, but denoted as marginal (± in Table 2).
For amnestic MCI, subjects had to have deﬁcits on one test
of memory with a score ≥2SD outside the age-adjusted
normal range, deﬁcits on one test of memory with a score
≥1.5SD outside of the normal range if accompanied by a
score on a nonmemory test ≥1SD , or deﬁcits on at least
two memory tests with scores at least ≥1SD outside the age-
adjusted normal range. To establish cognitive impairment
for nonamnestic MCI, subjects had to have a nonmemory
cognitive test with a score ≥2SD outside the normal range,
or two or more nonmemory cognitive tests with deﬁcits at
least ≥1SD outside the age-adjusted normal range.
Based on the initial NP test scores, subjects were either
diagnosedasamnesticMCI,nonamnesticMCI,orcombined
type MCI. Four subjects did not initially meet criteria for
MCI, but were diagnosed at later time points. In addition,
ﬁvesubjectsalsometclinicalcriteriafor(andwerediagnosed
with)mildtomoderateAD.Furthermore,11subjectsdidnot
meet criteria for either MCI or AD. This latter subset had
subclinical symptoms and/or were normal but at high risk
for development of AD based on the criteria above.
2.3. Control Database. The normal control database was
collected for general use in comparison with scans from
patients referred for PET brain evaluation. This control
database was collected with the approval of the Institutional
Review Board of the Louisiana State University Health
Science Center at Shreveport. All prospectively identiﬁed
subjects were recruited by advertisement and fully informed
of all risks, and they signed consent forms. Only subjects
older than 50 that met the criteria (n = 28) were used
for the current review. For inclusion in the normal control
PET database, subjects had to be physically healthy with no
neurological or psychiatric illness, have a normal physical
exam, have no memory complaints, and have normal
results on basic cognitive screening tests (Folstein Mini-
Mental State Exam ≥27, and Clock Drawing Test = 4).International Journal of Alzheimer’s Disease 3
Table 1: Demographics.
Subjects Gender (M/F) Age ± SD min age max age Education MMSE
Standard dataset 14/14 65.2 ±9.05 1 8 21 5 ±1.73 28.9 ±0.96
Patients 15/16 71.3 ±8.3
∗ 56 84 14.5 ±1.98 28.4 ±2
∗P = .01.
Table 2: Results for subjects enrolled in the MCI early detection study.
Subject MMSE SML Dx SPM1 SPM2 PET1 PET2 12345
S001 30 −− − − − −
S005 30 −− − — − — −−
S006 28 −− − − − − −
S008 29 −− − − − − n ±n ±nc −
S017 30 −− − − − − cc ±na
S020 30 −− − − − − ± n ±nc±n ±n
S025 29 −− − − − − n ±nn
S009 27 −− ± + −− ± n −
S002 28 −− + ± ++ c ±n ±nc
S003 27 −− ++−− n ±nn ±n
S012 30 + − ++− +
S039 29 + (±nMCI) −−− − ± n −
S015 29 + nMCI −−− − na ±n −
S028 28 + nMCI −−− − ± n ±na±n −
S019 30 + nMCI −−− − n ±n ±n ±n
S027 28 + cMCI −−− − cacca
S034 29 + cMCI −−+ − ccca
S010 29 + cMCI −±+ cacac
S014 30 + (cMCI) + + + − c ±n ±a
S016 27 + (cMCI) ± + −− c ±n ±a
S018 29 + aMCI ±−− − ± aa c±a −
S022 30 + cMCI + + −− caaca
S013 28 + (±nMCI) + ++ − + ±n ±n ±n
S023 25 + cMCI + ++ −− ccccc
S021 29 + nMCI ++ ++ −− n ±nc c
S032 27 + cMCI +++ — + — cccc−
S031 22 + AD +++ — + — ccccc
S033 25 + AD +++ — + — cc−−−
S038 25 + AD +++ — + — c −−−−
S040 25 + AD +++ — + — ccc−−
S041 26 + AD +++ +++ −− ccccc
Subj: Subject ID, MMSE: Mini-mental State Exam score, SML: subjective memory loss, Dx: Diagnosis, SPM: Consistent with possible MCI/AD based on
inspection of SPM statistical map, PET: Consistent with possible MCI/AD based on inspection of PET scan. There were two PET scans obtained for each
patient. One at study initiation and one at the end of the three year study. These are represented by the “1” and “2” subscripts for SPM and PET, respectively.
NP testing was done at ﬁve timepoints during the three year study, and results for these ﬁve examinations are shown in the columns on the right (1 through
5). NP testing: (blank): normal, a: amnestic, n: nonamnestic, (−): no data.
Extensive neuropsychological testing was not completed as
a cost/beneﬁt analysis indicated that the yield would be
minimal in a normal population with no subjective memory
loss. All had radiologically normal or unremarkable MRI
scans. PET scans were also clinically reviewed by the nuclear
medicine physicians utilizing subjective criteria and found
to be normal or unremarkable. Furthermore, individual
PET scans were removed from the control group and then
compared to the remainder of the control group in a “jack-
knife” fashion, and subjects with PET metabolism changes
in a pattern suspicious for the potential of developing
dementia (deﬁcits in medial temporal, lateral temporal,4 International Journal of Alzheimer’s Disease
posterior cingulum “cortex”, and posterior parietal regions)
were excluded. Demographics for the 28 subjects included in
the standard are shown in Table 1.
2.4. PET Image Acquisition and Processing. [18F]-ﬂuoro-
deoxyglucose (FDG) positron emission tomography (PET)
scans were completed at the beginning and at the end of the
three-yearperiod.AllPETscanswereacquiredandprocessed
in the same way from the same scanner. All patients were
informed to stop any medications potentially aﬀecting brain
function 24 hours prior to the study, fast for at least 6
hours prior to the study, and were ensured to have a blood
glucose level of less than 200mg/dL before administering
the radiotracer. All patients were injected intravenously with
approximately15mCi(555MBq)of 18F-FDG in a room with
low ambient noise and light while resting comfortably on a
bed. PET images of the brain were obtained 60 minutes later
on a GE Advance PET scanner (General Electric Company,
Milwaukee,WI).Emissionimagesofthebrainwereobtained
for 10 minutes per bed position as a static acquisition in 2D
mode followed by a 2 minute per bed position transmission
scan. The images were reconstructed with ordered subset
expectation maximization algorithms and segmented atten-
uationcorrection.ImageswereexportedinDICOM(NEMA,
Rosslyn, VA) format, and an Analyze 7.5 (Mayo Clinic,
Rochester, MN) compatible image was generated from the
DICOM slices. This image was imported into the Statistical
Parametric Mapping software (SPM, version 8, Wellcome
Department of Imaging Neuroscience, University College
London),whereitwasspatiallynormalizedintostandardized
space (using default settings of 12-parameter linear aﬃne
and nonlinear basis functions) and ﬁltered with an 8mm
isotropic Gaussian ﬁlter [13].
2.5. PET Image Review and Analysis. The PET brain images
obtained from individual patients were reviewed and inter-
preted in the standard clinical fashion using subjective visual
interpretation on the GE Advance workstation by one of two
experienced nuclear medicine physicians. They were blinded
to the diagnosis and to the results of the objective SPM
analysis.
For objective analyses, PET brain images from individual
patients were compared to the control database using voxel-
by-voxel analysis in SPM [14]. Since there is a small but
signiﬁcant diﬀerence in the mean age of the control group
and the subjects in the study, age was entered as a nuisance
covariate in the SPM analyses. SPM generates an SPM(T)
statistic for the entire brain image that is then converted to
the normally distributed Z-score. This 3D Z-score map is
thensurfacerenderedoroverlaidonaxialslicesofacanonical
image for viewing. An SPM(T) score of 2 and spatial extent
of 100 constituted the statistical threshold. This threshold
is lower than that used in typical statistical evaluations.
T h ej u s t i ﬁ c a t i o nf o rt h i si st w o - f o l d .T h e r ei sa nap r i o r i
hypothesis inherent in evaluation of patients with memory
loss or cognitive decline that deﬁcits in metabolism are
expectedincertainspeciﬁcregions.Furthermore,thepattern
of hypometabolism, if present and consistent with early
possible AD, is of signiﬁcance itself, at any threshold. The
speciﬁc pattern of metabolic deﬁcits putatively associated
with neurodegenerative changes due to early Alzheimer’s
disease process is described below and discussed later in the
paper.
FDG-PET scans were evaluated using the SPM results
in a similar fashion to the clinical readings, except that
the SPM(Z) map using the above threshold was used to
look for patterns of decreased metabolism consistent with
possible AD, rather than the PET scan per se. Metabolic
deﬁcits in posterior parietal, lateral temporal, posterior
cingulum, medial temporal, basal nuclear, and/or posterior
hippocampal regions present at this threshold were looked
for. PET image maps with smaller (less than 250 voxels),
less signiﬁcant (Z<3), and/or isolated (2 regions or less)
metabolic deﬁcits were considered negative, as these ﬁndings
may occur by chance at the low threshold used. Image maps
with metabolic deﬁcits that were larger than 250 voxels, had
Z scoreshigherthan3,and/orhadtwoormoreregionsinthe
areas being searched were then further evaluated and graded
on a score from marginal (±) to strongly positive (+++),
depending on the spatial extent, Z score, number of regions,
and presence of a “dog-leg” pattern. Results are presented in
Table 2. Six subjects (denoted by —) did not complete the
second PET scan.
3. Results and Discussion
Figure 1 shows four example subjects (S017: no diagnosis,
negative SPM evaluation, S003: no diagnosis with positive
SPM evaluation, S021: MCI with positive SPM evaluation,
and S040: AD). There are some features that are common
across all three examples with positive ﬁndings (and indeed,
across most subjects detected with SPM as being consistent
with possible early MCI/AD). This is shown most clearly in
the patient with AD. This patient has deﬁcits clearly visible
on the actual PET scan, which shows up prominently on
the SPM Z-map, both overlaid on cross sections and are
surface rendered. With AD, the pattern of brain metabolism
deﬁcits observed on FDG PET brain scans is characteristic
and well established, with bilateral posterior parietal and
lateral temporal deﬁcits forming the “dog-leg” pattern that
is commonly seen [4, 5, 15, 16] and present on this scan
as well, more prominently on the left (all images including
surface renderings are in radiological orientation). However,
all three subjects with positive ﬁndings shown (S003, S021,
S040) have both posterior temporal and posterior parietal
deﬁcits in metabolism. Also in all three subjects, posterior
cingulum hypometabolism is shown. Modern techniques
involving statistical analyses typically ﬁnd posterior cin-
gulum cortex metabolic decline [17, 18], but it is often
diﬃcult to see these on the actual PET scan until later in
the disease process. Medial temporal lobe hypometabolism
is not uncommonly seen, especially in earlier stages of
the disease process, but has been reported to have more
variability [19, 20]. In our present study, we did not
examine or consider frontal metabolic deﬁcits. Frontal lobe
hypometabolism is not uncommonly found in patients withInternational Journal of Alzheimer’s Disease 5
MCI/AD, but is nonspeciﬁc. One previous study found that
patients with MCI that did not convert to AD had mainly
frontal hypometabolism [20]. Furthermore, PET studies of
depression can be associated with frontal hypometabolism
[21], and depression is commonly found comorbid with
AD [11]. We did not exclude patients with depression from
the current study but also did not examine frontal lobe
metabolism, speciﬁcally because of this factor.
Table 2 presentsasummaryofthe resultsfromthisstudy.
Initially, subjects were diagnosed based on clinical presen-
tation and criteria for MCI or AD. Subjects had to meet
standard criteria for MCI to be diagnosed (e.g., subjective
memory loss) [12]. There were 11 subjects that did not
initially meet criteria for either MCI or AD and 15 who did
meet these criteria (one marginal). Four of these 15 subjects
did not initially meet criteria, but subsequently did meet the
criteria for an MCI diagnosis (two marginally so) later in
the study (in parentheses in Table 2). Of the 11 subjects who
never met MCI criteria, there were seven subjects who had
NP deﬁcits but did not have subjective memory loss criteria
for MCI and one who had subjective memory loss but never
hadNPdeﬁcits.NPtestingwasvariablethroughoutthestudy
in 20 of the 31 subjects. These 20 either had time points
where NP test scores were normal (either initially or later in
the longitudinal study) or had time points that met criteria
for a diﬀerent subtype of cognitive impairment. Of the 15
subjectsdiagnosedwithMCI,13hadvariableNPresultsover
the time points measured. Of the 11 subjects who did not
meet MCI or AD criteria, four were consistently negative,
and seven had variably positive results. There was variability
within subjects with regards to both the presence of and the
category of neuropsychological deﬁcit found. For instance,
subject 016 was normal, then had a combined deﬁcit, after
that became nonamnestic, and ﬁnaly, amnestic.
These results appear to reveal several factors, particularly
evident in individuals with mild or prodromal disease.
First, it is very likely that practice eﬀects impacted patient
performanceacrosstheﬁveassessments,sometimesresulting
in “normal” scores or lack of expected reductions in scores
in otherwise aﬀected individuals. Furthermore, individual
patient variability, including both short-term diﬀerences in
performance associated with their disease as well as variabil-
ityattributabletoexternal,nondisease-relatedfactorssuchas
stressorfatiguecouldhaveplayedarole.Thismayhaveledto
initial misclassiﬁcation of some subjects, especially because
ﬁve subjects who met MCI criteria had no PET ﬁndings
consistent with possible early AD. Furthermore, the presence
ofNPdeﬁcitsinthosewhoareatriskbutwhodenysubjective
memory loss is not unexpected, as recently published
results demonstrate similar ﬁndings [22]. Binder and others
examined variability in NP testing in healthy adults and
found that deﬁcits were common at low thresholds (1SD)
and still present at higher thresholds (2SD). Other reports
found that subjects diagnosed with MCI were sometimes
reclassiﬁed as either normal or other MCI subtype at a
follow-up visit [23, 24]. Thus, the presence of abnormalities
(especially marginal abnormalities) in subjects who are at
risk are not unexpected, and the intrasubject variability in
NP results is also consistent with the extant literature.
Standard (subjective visual) FDG-PET scan clinical
evaluation initially detected nine of the subjects enrolled in
the study. Five of these subjects (all diagnosed with AD) did
not complete the second PET scan. At the second time point,
only three of the remaining 25 subjects were detected. While
these numbers seem low, the reason for this is that 15 of the
subjects were initially preclinical or in fact normal (although
four eventually met criteria for MCI). In addition, even
subjects diagnosed with MCI had mild disease, as indicated
bytheMMSE(meanMMSEforpatientswithMCIwas28.4).
The SPM evaluation initially detected 14 subjects as
having changes in brain metabolism consistent with possible
early MCI or AD that and three subjects as borderline
(total = 17). Two of these three subjects were read as positive
at the second time point, and one was read as negative (no
ﬁndings). All subjects that were detected initially were also
detected on the second PET scan save for this subject (S018).
One subject who was initially negative did not complete the
second scan, and ﬁve subjects with more advanced disease
also did not complete the latter time-point scan. The ﬁve
subjects diagnosed with possible AD had SPM objective
evaluations that were all strongly positive and consistent
with possible AD. Only one of these ﬁve was rescanned and
remained strongly positive.
The variability in ﬁndings here deserves mention. While
it would be expected that subjects with a diagnosis of
MCI and/or ﬁndings on SPM objective evaluation would
progress, not all subjects would. Some subjects progressed,
some had no substantial change, and two actually appeared
to have SPM ﬁndings that were smaller on the second
scan. Bozoki and others recently discovered the presence of
“cognitive plateaus” in 22% of the patients with AD that they
studied (n = 243) [25]. The average length of the plateau
was 3.6 years, with the range being 3 to 7 years. This is
important in that this could be a reﬂection of a “metabolic
plateau” where there is a lack of progression in the deﬁcits in
hypometabolism and could help explain the lack of change
in some subjects in this present study. Another report
demonstrated that higher premorbid intellectual function (a
measure of cognitive reserve) can impact not just cognitive
performance but also FDG-PET brain metabolism [26].
It is thus possible that subjects in the preclinical or very
early stages of AD might have ﬁndings on objective PET
evaluation, but have little to no subjective and/or objective
memory loss.
ThediagnosisofMCIismadebaseduponthepresenceof
subjective memory loss with objective cognitive impairment
on NP testing. In this study, we found that 15 subjects
met criteria for a diagnosis of MCI either initially or at
a subsequent time point. Of these, six were consistently
negative with respect to metabolic deﬁcits on objective SPM
evaluation. Thus, there were a subset of subjects with no
diagnosis who had SPM ﬁndings and a subset of subjects
diagnosed with MCI who had no SPM ﬁndings.
In summary, there was little that was consistent with
respect to the subjects diagnosed with MCI or the at-risk
subjects who did not meet criteria. There were some in
each category who had no SPM ﬁndings and some that did.6 International Journal of Alzheimer’s Disease
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Figure 1: Example results from four subjects in the study. Each row is one subject. The color bar in each row represents the scale for the
Z-score in that subject. The left column depicts the SPM Z-map surface rendering, the middle column depicts the SPM Z-map overlaid on
a canonical template image in cross section, and the right column shows the FDG-PET scan in cross-section.International Journal of Alzheimer’s Disease 7
Since memory loss and objective impairment are both
requirements for a diagnosis of MCI, there is of course close
association here, but even in this subgroup, nine of the
10MCI subjects did not maintain consistent type of deﬁcit
on NP scores.
3.1. Prediction of MCI/AD Diagnosis. The current standard
of care for diagnosis of AD is a diagnosis of exclusion made
clinically. The gold standard remains a brain biopsy to look
for neuroﬁbrillary tangles and amyloid plaques; however,
this is rarely done until autopsy. The use of FDG-PET has
been considered for augmentation of the standard of care to
improve accuracy and early detection, but cost and accuracy
with regard to early detection of MCI were problematic [27].
However, previous evaluations in this respect did not include
the use of objective statistical evaluation of FDG-PET scans.
Two current large ongoing studies (ADNI: Alzheimer’s
Disease Neuroimaging Initiative, and NEST-DD: Network
for Standardization of Dementia Diagnosis) also support the
use of objective statistical image analyses for early detection
of AD [28].
Our research demonstrates a possible advantage with
objective SPM evaluation over standard (subjective visual)
clinical interpretation in that clinically relevant patterns of
hypometabolism were observed in some subjects not yet
diagnosed and were not observed in some subjects who were
diagnosed with MCI. It is worth mentioning that the former
may represent false positive identiﬁcation and the latter false
negatives. While these results presented here are variable
and somewhat confusing, it is important to understand the
context of a group of subjects consisting mostly of at-risk
cognitively normal or very early clinical subjects (save for
ﬁve patients with AD, included as positive controls). In this
populationontheborderlineofpossibledevelopmentofAD,
all three detection algorithms (NP testing, standard visual
interpretation, objective SPM interpretation) were variably
ineﬀective. Where there was agreement among diagnosis
and all three algorithms, there was clarity. However, whether
either subjects with no SPM ﬁndings and positive NP
ﬁndings (and vice-versa) eventually develop AD must be
evaluated at future time points, and so this work must
remain preliminary. Thus, while the presence of false
positives or negatives cannot be determined for certain at
this time, it is possible that objective statistical evaluation
of FDG-PET brain scans could improve the detection
rate for nuclear medicine physicians. While these results
must be classiﬁed as preliminary (diagnosis of AD is not
deﬁnitive—especially in at-risk cognitively normal subjects),
it is supported by the extant literature demonstrating
FDG PET detection (via objective statistical evaluation) in
premorbid subjects, both across groups [6–8] and in other
previous studies examining individual subjects [29–32].
The pattern of deﬁcits in metabolism observed in
Alzheimer’s disease is consistent: posterior cingulate, pos-
terior parietal, lateral temporal, medial temporal/hippo-
campus, sometimes basal nuclear and variably frontal
hypometabolism. There can be variance within this pattern
(e.g., some cases are unilateral, some are bilateral) but
the regions themselves are highly consistent. Practically, all
published articles on FDG-PET imaging of AD spanning 30
years ﬁnd hypometabolism in these regions (see e.g., [1–3]).
As early as 1995, Minoshima calls this pattern “diagnostic”
when referring to the pattern of hypometabolism seen in the
parietal and temporal regions of FDG-PET brain scans from
patients with AD [33]. This pattern is a hallmark feature
of AD, and other neurodegenerative diseases have diverse
patterns of hypometabolism [2, 3, 31]( f o rr e v i e ws e e[ 32]).
With respect to the frontotemporal lobar dementias (FTLD),
Pick’s disease has a diﬀerent clinical picture, and the sta-
tistical map would demonstrate mostly the frontotemporal
patternofmetabolicdeﬁcits[34,35].Thesemanticdementia
variant of FTLD may be a potential diagnostic challenge, but
thepatternofmemorylossisdiﬀerent(semanticversusshort
term), and the metabolic pattern is typically restricted to the
temporal lobes, especially early in the disease process [36]. In
AD, deﬁcits in metabolism may appear in medial temporal
regions, but they also quickly appear in the posterior cingu-
lum and/or posterior parietal cortices, and typically appear
in these latter regions ﬁrst. Lewy body dementia would be
the most problematic diﬀerential diagnostic issue, as it has
a partially similar pattern of metabolic deﬁcits and a clinical
presentation that could be confused. However, the posterior
metabolic ﬁndings are typically accompanied by a distinctive
occipitallobehypometabolism[2,37,38].Vasculardementia
has a pattern that depends upon the region of the vascular
lesion. It is possible to have vascular lesions and subsequent
hypometabolic ﬁndings in regions that coincide with those
typically seen in AD; however, this would be atypical as pat-
ternsofvascularizationinhumansdonotpredisposetowards
infarctsinmedialtemporalorposteriorcingulumregions.In
addition, the clinical picture would once again be diﬀerent.
The standard of care in PET brain imaging for detection
of AD is subjective visual interpretation of the FDG-PET
brain scan. The purpose of this paper was to demonstrate
an advantage of objective SPM evaluation over the standard
clinical (subjective visual) PET brain image evaluation, and
in this regard was met with a measured degree of success.
A key concept is that objective statistical evaluation of PET
brain image data has the potential to signiﬁcantly extend the
nuclearmedicinephysician’sabilitytoprovidepertinentdata
to the referring physician to improve diagnostic accuracy.
Previous evaluations of PET imaging as a standard for
detection of AD determined that PET imaging for early
detection was “optional” (reviewed in [27]). However,
these previous examinations did not consider the utility of
objective statistical analyses of PET brain imaging data; they
just considered subjective visual interpretation. This is a
critical and overlooked detail, and hopefully this and other
studies will provide the impetus for re-evaluation (inclusive
of objective analyses) of FDG-PET in early detection of
possible AD. As demonstrated here in this study, objective
PET evaluation increased the detection rate in patients
diagnosed with early MCI from 5/15 to 9/15 subjects
(inclusiveofbothtimepoints).Further,theconsistentlackof
objectivePETﬁndingsintheothersubjectsmaybeindicative
of misdiagnosis with MCI. SPM evaluation also detected
changes in four subjects who did not meet criteria for MCI
(one was also detected by standard clinical PET evaluation),8 International Journal of Alzheimer’s Disease
one of whom had no NP deﬁcits, indicating the presence of
metabolicchangesthatcouldheraldtheeventualonsetofAD
in these at-risk subjects. However, given the uncertainty in
diagnosis at this stage of the disease process, more sensitive
detection of hypometabolic regions possibly representing
very early AD could be problematic if used in isolation. If
used as a tool for the nuclear medicine physician to provide
more sensitive answers to referring physicians, it may be of
beneﬁt in cases with clinically correlated illness.
4. Conclusions
These results indicate that objective statistical analysis of
FDG-PET brain images has the potential to detect changes in
brain metabolism that appear consistent with the neurode-
generative changes associated with AD in individual patients
diagnosed with MCI as well as in the at-risk cognitively
normal state at a higher rate than with standard clinical PET
brain scan evaluation alone. This is an important ﬁnding,
as the need for early detection grows as our ability to treat
this neurodegenerative disease improves. Blood tests that
screen for early changes in AD progression may eventually
become readily available and sensitive enough for screening
purposes; however, Alzheimer’s disease is a brain disorder,
and thus examining actual brain activity will always be an
optimal means of assessing disease state. Given that there are
now several FDA approved software packages available [10],
objective evaluation of FDG PET brain scans for the early
detection of metabolic deﬁcits related to the neurodegener-
ative changes of Alzheimer’s disease in the MCI stage is cur-
rentlyavailabletomostPET imaging centers.Theseobjective
software packages are speciﬁcally designed to function as
tools that improve detection capability and thus enable the
nuclear medicine physician to aid the referring physician in
early diagnosis and subsequent treatment decisions.
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